Comparison of the Efficacy of Adding Inhaled Levofloxacin and Colistin to a Basic Regimen of Colistin and Meropenem in the Treatment of Ventilator-associated Pneumonia Caused by Multidrug-resistant Gram-negative Bacteria: A Randomized Open-label Clinical Trial
Authors:
Open Access
- 1 January 2025
- journal article
- Published by Wolters Kluwer Health in Journal of Research in Pharmacy Practice
- Vol. 14 (1) , 9-17
Abstract
Objective: Ventilator-associated pneumonia (VAP) caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) is a major intensive care unit challenge, particularly in Iran, due to limited antibiotic options. This study compared the efficacy of adding levofloxacin and colistin inhalation form to the baseline regimen of colistin and meropenem in treating VAP caused by MDR-GNB. Methods: Patients with VAP were randomly assigned to the colistin group ( n = 24), receiving 2 million international unit (MIU) every 8 h, and the levofloxacin group ( n = 22), receiving 250 mg every 12 h, alongside intravenous colistin (4.5 MIU every 12 h) and meropenem (1 g every 8 h). Clinical improvement using the Clinical Pulmonary Infection Score (CPIS) on days 1, 5, and 7, the clinical response on day 7, and inflammatory markers (erythrocyte sedimentation rate and C-reactive protein) on days 1, 3, 5, and 7 were evaluated. Findings: CPIS scores significantly decreased in both groups: Colistin (−3.67 ± 2.14, P < 0.001) and levofloxacin (−4.41 ± 1.71, P < 0.001), with no intergroup difference ( P = 0.200). The clinical response analysis indicated that levofloxacin was associated with fewer treatment failures and more partial responses, whereas colistin demonstrated higher rates of complete response; however, these differences were not statistically significant ( P > 0.05). Acute kidney injury occurred only in the colistin group ( n = 8; 33.3%). Bronchospasm and cough occurred in one levofloxacin patient (4.54%), showing a significant difference in adverse effects ( P = 0.004). Mortality rates were higher in the colistin group ( n = 17; 70.8%) compared to the levofloxacin group ( n = 10; 45.5%), though this difference was not statistically significant ( P = 0.08). Conclusion: Levofloxacin inhalation may be considered an effective alternative to colistin inhalation for treating VAP caused by MDR-GNB. It offers similar efficacy and lower nephrotoxicity.Keywords
This publication has 34 references indexed in Scilit:
- Multidrug-resistant Gram-negative bacterial infectionsThe Lancet, 2025
- The Unfulfilled Promise of Inhaled Therapy in Ventilator-Associated Infections: Where Do We Go from Here?Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2022
- International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2012-2017: Device-associated moduleAmerican Journal of Infection Control, 2020
- Ventilator-associated pneumonia in adults: a narrative reviewIntensive Care Medicine, 2020
- Size distributions of droplets produced by ultrasonic nebulizersScientific Reports, 2019
- Activity of levofloxacin in combination with colistin against Acinetobacter baumannii: In vitro and in a Galleria mellonella modelJournal of Microbiology, Immunology and Infection, 2017
- Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical AspectsDrugs, 2017
- Epidemiology of multidrug-resistant Gram-negative pathogens isolated from ventilator-associated pneumonia in ICU patientsJournal of Global Antimicrobial Resistance, 2017
- Time–kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistinEuropean Journal of Clinical Microbiology & Infectious Diseases, 2014
- Clinical pulmonary infection score and C-reactive protein in the prediction of early ventilator associated pneumoniaThe Egyptian Journal of Chest Diseases and Tuberculosis, 2013